Purpose: Renal cell carcinoma (RCC) is the 12th most common cancer and its incidence is in increasing trend worldwide.

Methods: This study was carried out at Urosurgical ward of Yangon Specialty Hospital including (87) cases of clinically suspected renal cell carcinoma patients. Preoperative serum samples were collected and histologically proven clear cell renal cell carcinoma cases were selected and miRNA level were determined by quantitative reverse-transcriptase polymerase chain reaction.

Results: Clear cell renal cell carcinoma occurred in all age groups ranging from 24 to 82 years. The most commonly affected age group were 41-60 years including 52 patients (56.5%) and male to female ratio was 1.6:1. Serum miRNA-210 level was found to be significantly high in relation to normal and the receiver-operator characteristic (ROC) curve demonstrated the most promising sensitivity and specificity when the miRNA-210 level was set at 8.13 × 103copies/ul. Most of the patients were grade 2 histology followed by grade 3 and grade 4. Grade 1 histology cases were not found in this study. When analyzing with chi squared test, the mean serum miRNA-210 level of the total study population, (8.3057 × 104 copies/µl) was used to categorize the data into two groups in which those having serum miRNA-210 level below mean and those with the mean and above in relation to the low and high grades as well as low and high stages of RCC. There was statistically significant association between miRNA-210 expression of lower grades (grade 1 & 2) and higher grades (grade 3 &4) of clear cell RCC (p = 0.0001). There was also statistically significant association between miRNA-210 expression of lower stages (Stage I & II) and higher stages (Stage III &IV) of RCC (p = 0.005).

Conclusion: The upregulated miRNA-210 expression could estimate prognosis for active surveillance from patients having undergone surgical resection.

Citation Format: Yin Min Htun, Moh Moh Htun, Khin Thida Aung. Serum miRNA-210 Level in Clear Cell Renal Cell Carcinoma [abstract]. In: Proceedings of the 9th Annual Symposium on Global Cancer Research; Global Cancer Research and Control: Looking Back and Charting a Path Forward; 2021 Mar 10-11. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2021;30(7 Suppl):Abstract nr 93.